MA45801B1 - Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine - Google Patents
Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptineInfo
- Publication number
- MA45801B1 MA45801B1 MA45801A MA45801A MA45801B1 MA 45801 B1 MA45801 B1 MA 45801B1 MA 45801 A MA45801 A MA 45801A MA 45801 A MA45801 A MA 45801A MA 45801 B1 MA45801 B1 MA 45801B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- antigen
- lepr
- binding fragments
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne des anticorps et des fragments de liaison à l'antigène d'anticorps qui se lient au récepteur de la leptine (lepr), et des procédés de leur utilisation. Selon certains modes de réalisation, l'invention concerne des anticorps et des fragments de liaison à l'antigène d'anticorps qui se lient au lepr et antagonisent la signalisation par lepr. Dans certains modes de réalisation, l'invention concerne des anticorps et des fragments de liaison à l'antigène d'anticorps qui se lient au lepr en présence ou en l'absence de leptine. Dans d'autres modes de réalisation, l'invention comprend des anticorps et des fragments de liaison à l'antigène d'anticorps qui présentent un agonisme partiel de la signalisation lepr. Les anticorps et les fragments de liaison à l'antigène de la présente invention sont utiles pour le traitement de divers états, comprenant, entre autres, la cachexie liée à l'insuffisance cardiaque congestive, la cachexie pulmonaire et la cachexie cancéreuse, les troubles auto-immuns tels que la maladie intestinale inflammatoire, le lupus érythémateux, la sclérose en plaques, le psoriasis, les maladies cardiovasculaires, l'hypertension artérielle, les troubles neurodégénératifs, la dépression, le cancer tel que le carcinome hépatocellulaire, le mélanome, le cancer du sein, et d'autres maladies et troubles associés à ou provoqués par une signalisation de leptine élevée.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419062P | 2016-11-08 | 2016-11-08 | |
| PCT/US2017/060690 WO2018089532A1 (fr) | 2016-11-08 | 2017-11-08 | Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45801A1 MA45801A1 (fr) | 2020-07-29 |
| MA45801B1 true MA45801B1 (fr) | 2021-11-30 |
Family
ID=60409473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45801A MA45801B1 (fr) | 2016-11-08 | 2017-11-08 | Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10550192B2 (fr) |
| EP (2) | EP4613772B1 (fr) |
| JP (4) | JP7042816B2 (fr) |
| KR (1) | KR102563568B1 (fr) |
| CN (1) | CN110167965A (fr) |
| AU (2) | AU2017359439B2 (fr) |
| CA (1) | CA3043365A1 (fr) |
| CL (3) | CL2019001263A1 (fr) |
| CO (1) | CO2019004672A2 (fr) |
| DK (1) | DK3538554T3 (fr) |
| EA (1) | EA201991075A1 (fr) |
| ES (1) | ES3040144T3 (fr) |
| FI (1) | FI3538554T3 (fr) |
| HR (1) | HRP20251165T1 (fr) |
| HU (1) | HUE073276T2 (fr) |
| IL (2) | IL266426B (fr) |
| LT (1) | LT3538554T (fr) |
| MA (1) | MA45801B1 (fr) |
| MX (2) | MX2019005397A (fr) |
| MY (2) | MY203682A (fr) |
| PH (1) | PH12019500988A1 (fr) |
| PL (1) | PL3538554T3 (fr) |
| PT (1) | PT3538554T (fr) |
| RS (1) | RS67214B1 (fr) |
| SG (1) | SG10201913470SA (fr) |
| SI (1) | SI3538554T1 (fr) |
| SM (1) | SMT202500327T1 (fr) |
| UA (1) | UA127678C2 (fr) |
| WO (1) | WO2018089532A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI824372B (zh) | 2015-10-12 | 2023-12-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| MA45801B1 (fr) | 2016-11-08 | 2021-11-30 | Regeneron Pharma | Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine |
| SG11202005146VA (en) | 2017-12-18 | 2020-06-29 | Regeneron Pharma | Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof |
| SMT202500283T1 (it) | 2018-04-06 | 2025-09-12 | Regeneron Pharma | Un anticorpo agonista del recettore della leptina da utilizzare per aumentare la massa ossea in un soggetto affetto da disfunzione metabolica o ipoleptinemia |
| WO2020016160A1 (fr) * | 2018-07-16 | 2020-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthode de traitement de maladies neurologiques |
| CN113195532B (zh) * | 2018-12-18 | 2025-04-11 | 瑞泽恩制药公司 | 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| KR20230038524A (ko) * | 2020-07-17 | 2023-03-20 | 스미토모 세이카 가부시키가이샤 | 흡수체 |
| BR112023004716A2 (pt) * | 2020-09-15 | 2023-05-09 | Regeneron Pharma | Uso de agonistas de lepr para dor |
| CN118436632B (zh) * | 2024-07-05 | 2024-08-30 | 四川大学华西第二医院 | Teriflunomide在制备预防和/或治疗原发性纤毛不动综合征的药物中的用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451523B1 (en) | 1994-09-14 | 2002-09-17 | Interneuron Pharmaceuticals, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| US5912123A (en) | 1994-09-14 | 1999-06-15 | Progenitor, Inc. | Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology |
| US5856098A (en) | 1994-09-14 | 1999-01-05 | Progenitor, Inc. | Detection of a leptin receptor variant |
| US5643748A (en) | 1994-09-14 | 1997-07-01 | Progenitor, Inc. | HU-B1.219, a novel human hematopoietin receptor |
| US6977240B1 (en) * | 1995-11-27 | 2005-12-20 | Millenium Pharmaceuticals, Inc. | Methods of using the OB receptor antibodies to treat bodyweight disorders |
| US6482927B1 (en) | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
| US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| AU721129B2 (en) | 1996-01-08 | 2000-06-22 | Genentech Inc. | WSX receptor and ligands |
| US7063958B1 (en) | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
| AU2476301A (en) | 1996-01-16 | 2001-05-24 | Rockefeller University, The | DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof |
| AU1833197A (en) | 1996-01-18 | 1997-08-11 | Progenitor, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| AU731685C (en) | 1996-01-23 | 2002-08-22 | Indevus Pharmaceuticals, Inc. | Methods for using the obese gene and its gene product to stimulate hematopoietic development |
| US7067472B1 (en) | 1996-06-04 | 2006-06-27 | The Scripps Research Institute | Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies |
| US5965521A (en) | 1997-02-25 | 1999-10-12 | Eli Lilly Company | Pulsatile delivery of leptin receptor ligands |
| IL120733A0 (en) | 1997-04-29 | 1997-08-14 | Yeda Res & Dev | Leptin as an inhibitor of cell proliferation |
| US6696411B1 (en) | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
| AU767068B2 (en) | 1999-06-11 | 2003-10-30 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of leptin activity |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| FR2852397B1 (fr) | 2003-03-10 | 2005-04-29 | Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal. | |
| ES2289235T3 (es) * | 2003-08-21 | 2008-02-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Nuevo antagonista de leptina. |
| DE10353593A1 (de) * | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
| US7863240B2 (en) | 2004-10-08 | 2011-01-04 | Enzo Therapeutics, Inc. | Methods and uses of leptin in hepatocellular carcinoma |
| US8969291B2 (en) | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
| EP1812038A1 (fr) | 2004-11-18 | 2007-08-01 | VIB vzw | Domaine de fibronectine iii servant d'antagonistes de recepteurs de la leptine |
| US7307142B2 (en) * | 2004-11-26 | 2007-12-11 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Leptin antagonists |
| CA2606102C (fr) | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation de la fonction d'effecteur d'anticorps par ingenierie de domaine "charniere" |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| GB0715216D0 (en) | 2007-08-03 | 2007-09-12 | Asterion Ltd | Leptin |
| US9221902B2 (en) | 2008-11-07 | 2015-12-29 | Fabrus, Inc. | Combinatorial antibody libraries and uses thereof |
| CN105859889B (zh) | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| RU2013139267A (ru) | 2011-02-10 | 2015-03-20 | Рош Гликарт Аг | Улучшенная иммунотерапия |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| FI3366705T3 (fi) | 2012-09-12 | 2023-07-28 | Genzyme Corp | Muuttuneen glykosylaation ja vähentyneen efektoritoiminnan omaavia fc:n sisältäviä polypeptidejä |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| RS57582B1 (sr) * | 2013-02-20 | 2018-11-30 | Regeneron Pharma | Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca |
| EP3108255B1 (fr) | 2014-02-18 | 2020-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques pour le traitement de maladies induites par la voie de signalisation du complexe nrp-1/obr |
| TWI824372B (zh) | 2015-10-12 | 2023-12-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| MA45801B1 (fr) | 2016-11-08 | 2021-11-30 | Regeneron Pharma | Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine |
-
2017
- 2017-11-08 MA MA45801A patent/MA45801B1/fr unknown
- 2017-11-08 SI SI201731619T patent/SI3538554T1/sl unknown
- 2017-11-08 JP JP2019523865A patent/JP7042816B2/ja active Active
- 2017-11-08 EP EP25187542.3A patent/EP4613772B1/fr active Active
- 2017-11-08 SG SG10201913470SA patent/SG10201913470SA/en unknown
- 2017-11-08 CA CA3043365A patent/CA3043365A1/fr active Pending
- 2017-11-08 LT LTEPPCT/US2017/060690T patent/LT3538554T/lt unknown
- 2017-11-08 MX MX2019005397A patent/MX2019005397A/es unknown
- 2017-11-08 HU HUE17801273A patent/HUE073276T2/hu unknown
- 2017-11-08 US US15/807,426 patent/US10550192B2/en active Active
- 2017-11-08 MY MYPI2022002957A patent/MY203682A/en unknown
- 2017-11-08 ES ES17801273T patent/ES3040144T3/es active Active
- 2017-11-08 RS RS20250925A patent/RS67214B1/sr unknown
- 2017-11-08 DK DK17801273.8T patent/DK3538554T3/da active
- 2017-11-08 EP EP17801273.8A patent/EP3538554B1/fr active Active
- 2017-11-08 PL PL17801273.8T patent/PL3538554T3/pl unknown
- 2017-11-08 UA UAA201906354A patent/UA127678C2/uk unknown
- 2017-11-08 AU AU2017359439A patent/AU2017359439B2/en active Active
- 2017-11-08 PT PT178012738T patent/PT3538554T/pt unknown
- 2017-11-08 HR HRP20251165TT patent/HRP20251165T1/hr unknown
- 2017-11-08 WO PCT/US2017/060690 patent/WO2018089532A1/fr not_active Ceased
- 2017-11-08 EA EA201991075A patent/EA201991075A1/ru unknown
- 2017-11-08 FI FIEP17801273.8T patent/FI3538554T3/fi active
- 2017-11-08 KR KR1020197016377A patent/KR102563568B1/ko active Active
- 2017-11-08 MY MYPI2019002549A patent/MY191256A/en unknown
- 2017-11-08 SM SM20250327T patent/SMT202500327T1/it unknown
- 2017-11-08 CN CN201780082335.4A patent/CN110167965A/zh active Pending
-
2019
- 2019-05-02 IL IL266426A patent/IL266426B/en active IP Right Grant
- 2019-05-03 PH PH12019500988A patent/PH12019500988A1/en unknown
- 2019-05-07 CO CONC2019/0004672A patent/CO2019004672A2/es unknown
- 2019-05-08 MX MX2023011233A patent/MX2023011233A/es unknown
- 2019-05-08 CL CL2019001263A patent/CL2019001263A1/es unknown
-
2020
- 2020-01-07 US US16/736,760 patent/US11535675B2/en active Active
- 2020-01-30 IL IL272358A patent/IL272358B/en unknown
- 2020-03-05 CL CL2020000549A patent/CL2020000549A1/es unknown
- 2020-04-16 CL CL2020001023A patent/CL2020001023A1/es unknown
-
2021
- 2021-12-21 JP JP2021206917A patent/JP2022031969A/ja active Pending
-
2022
- 2022-11-17 US US18/056,411 patent/US20230235068A1/en active Pending
-
2023
- 2023-05-02 JP JP2023076083A patent/JP7611292B2/ja active Active
-
2024
- 2024-05-31 JP JP2024088870A patent/JP7875904B2/ja active Active
-
2025
- 2025-02-28 AU AU2025201454A patent/AU2025201454A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45801A1 (fr) | Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine | |
| PH12022551750A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| MA40224B1 (fr) | Anticorps se liant aux protofibrilles ass améliorés | |
| MA31156B1 (fr) | Modulateurs de partenaires de liaison de la sclerostine pour traiter des troubles lies aux os | |
| WO2019014328A3 (fr) | Anticorps agonistes qui lient cd137 humain et leurs utilisations | |
| EA202092094A1 (ru) | Фенилпирролидиноновые агонисты формилпептидного рецептора 2 | |
| BR112022004986A2 (pt) | Anticorpos anti-tnfr2 e métodos de uso | |
| EA200870465A1 (ru) | Антагонисты рецептора il-8 | |
| MA46665B1 (fr) | Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y | |
| MA35345B1 (fr) | Proteines de liaisons a un antigene ayant une liaison accrue a fcrn | |
| DK1966244T3 (da) | Anti-il-6-antistoffer der forebygger bindingen af il-6 sammensat af il-6ralfa til gp130 | |
| TW200612908A (en) | Antibodies against human interleukin-13 and uses therefor | |
| MA29330B1 (fr) | Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires. | |
| FR3038517B1 (fr) | Utilisation de fragments fc modifies en immunotherapie | |
| MA30090B1 (fr) | Utilisation d'un antagoniste de CB1 pour le traitement des effets secondaires et des symptômes négatifs de la schizophrénie | |
| MA37946B1 (fr) | Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde | |
| EA202092593A1 (ru) | Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение | |
| EP4406592A3 (fr) | Molécules de liaison thérapeutiques | |
| DE602004031003D1 (de) | Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden | |
| ATE423100T1 (de) | Neue chinolinverbindungen, die dazu in der lage sind, sich an den cb2-rezeptor zu binden | |
| WO2003104761A3 (fr) | Mesure de peptides de melanocortine et utilisations correspondantes | |
| MA39555B1 (fr) | Mutagenèse dirigée d'anticorps trem-1 pour réduire la viscosité | |
| WO2024118923A3 (fr) | Anticorps agonistes de btla et leurs utilisations | |
| FR2856595B1 (fr) | Methodes et compositions pour le traitement de deficits cognitifs. | |
| WO2005106489A3 (fr) | Diagnostics et therapies s'appliquant a des maladies associees aux recepteurs 5 des chimiokines c-c (ccr5) |